Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Third Quarter 2023 Financial Results and Business Update

Monday, February 19, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: VolitionRx's Group CEO, Cameron Reynolds, provided an overview of the company's financial results for the third quarter of 2023. The report highlighted a collaboration with Sysmex and the filing of a new patent for the Nu.Q® NETs Test aimed at Ebola triage and treatment monitoring. These developments indicate ongoing progress in the company's strategic initiatives.
Price reaction · baseline $20.8 (2024-02-16 close) · clean, no other VNRX news in the window
day 0 close · peak
+1%

Market Sentiment Analysis

POSITIVE FACTORS

  • VolitionRx reported its third quarter 2023 financial results.
  • The company announced a collaboration with Sysmex.
  • A new patent was filed for the Nu.Q® NETs Test.

Full Press Release Details

Volition’s Group Chief Executive Officer, Cameron Reynolds provides an overview of the company’s third quarter 2023 financial results and business update

Related Articles

• Press Releases VolitionRx Announces Collaboration with Sysmex
• Press Releases VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

VolitionRx Announces Collaboration with Sysmex

VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What were the highlights of VolitionRx's Q3 2023 results?

VolitionRx highlighted its financial results, a collaboration with Sysmex, and a new patent for the Nu.Q® NETs Test.

Who is the CEO of VolitionRx?

Cameron Reynolds is the Group Chief Executive Officer of VolitionRx.

What is the purpose of the Nu.Q® NETs Test?

The Nu.Q® NETs Test is designed for Ebola triage and treatment monitoring.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare VolitionRx Q3 2023 financial results Sysmex
Last updated: Feb 19, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk